Medpace Holdings, Inc. $MEDP Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 28,703 shares of the company’s stock after selling 1,009 shares during the period. New York State Teachers Retirement System’s holdings in Medpace were worth $13,783,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Capital Fund Management S.A. increased its holdings in shares of Medpace by 129.5% during the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock worth $16,665,000 after purchasing an additional 18,287 shares during the period. Dorsey Wright & Associates acquired a new position in Medpace during the 3rd quarter worth about $5,082,000. Victory Capital Management Inc. boosted its position in Medpace by 32.9% in the 3rd quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock valued at $15,702,000 after buying an additional 7,565 shares during the last quarter. Capital Impact Advisors LLC raised its holdings in Medpace by 31.7% during the 3rd quarter. Capital Impact Advisors LLC now owns 26,995 shares of the company’s stock worth $13,880,000 after purchasing an additional 6,495 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after buying an additional 2,274 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $557.60 on Monday. The business has a 50-day moving average of $453.88 and a 200 day moving average of $496.19. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The firm has a market cap of $15.93 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.83 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the business earned $3.67 EPS. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MEDP shares. BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Barclays decreased their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Robert W. Baird lowered their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Royal Bank Of Canada lowered their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.